KLEANTHIS G. XANTHOPOULOS is the President and CEO of Anadys
Pharmaceuticals, Inc. Previously, he was a Vice President of Genomics
and Molecular Biology at Aurora Biosciences Corp., where he developed
and commercialized Aurora’s genomics business. Dr. Xanthopoulos was a
Section Head of the National Human Genome Research Institute at NIH and
he is currently an adjunct Associate Professor at the University of Utah
Medical School, Salt Lake City. Previously, he held an Associate
Professorship at the Karolinska Nobel Medical Institute, Stockholm,
Sweden. Dr. Xanthopoulos graduated from the Aristotle University of
Thessaloniki, Greece, and received both his MSc in Microbiology and PhD
in Molecular Biology from the University of Stockholm, Sweden. He is an
Onassis Scholar, a Greek Government Distinguished Fellow, the recipient
of Swedish National Sciences Foundation awards and was a National
Institutes of Health Fellow at the Rockefeller University, New York. He
is also the author of more than 60 peer review publications and a member
of several editorial boards.
